Cargando…
Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience
The long‐term effects of tyrosine kinase inhibitors (TKIs), including imatinib, and surgical intervention on advanced gastrointestinal stromal tumor (GIST) were evaluated. All 379 patients had metastatic or recurrent GIST and started 400 mg/d imatinib at the Asan Medical Center in periods 1 and 2 [2...
Autores principales: | Kim, Jwa Hoon, Ryu, Min‐Hee, Yoo, Changhoon, Chae, Heejung, Na, Hana, Beck, Moyoul, Kim, Beom Su, Yoo, Moon‐Won, Yook, Jeong Hwan, Kim, Byung Sik, Kim, Ki‐Hun, Kim, Chan Wook, Kang, Yoon‐Koo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434201/ https://www.ncbi.nlm.nih.gov/pubmed/30693663 http://dx.doi.org/10.1002/cam4.1994 |
Ejemplares similares
-
Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
por: Cho, Hyungwoo, et al.
Publicado: (2019) -
Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
por: Yoo, Changhoon, et al.
Publicado: (2019) -
Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors
por: Na, Young-Soon, et al.
Publicado: (2017) -
Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013) -
Intra-abdominal desmoid tumors mimicking gastrointestinal stromal tumors — 8 cases: A case report
por: Kim, Jwa Hoon, et al.
Publicado: (2019)